Skip to main content

FreeCME
About Us
Sign Up|Log In

FreeCME
About Us
All Products

Sign Up|Log In

Browse by Speciality Area

Hospital Management
Cardiology
Critical Care
Emergency Medicine
Infectious Disease
Integrative Medicine
Internal Medicine
Neurology
Obstetrics/Gynecology
Primary Care/Hospitalist

Browse by Product Type

Subscription Publications
Books & Study Guides

All Access Subscription

Get unlimited access to our full publication and article library.

Interested in Group Sales? Learn more

Home
Drug Formulary Review Archives
January 1, 2002

Drug Criteria & Outcomes: Tinzaparin formulary evaluation: DVT treatment

January 1, 2002

Issue Date: January 1, 2002

Table of Contents

Blockbuster sepsis drug drotrecogin alfa (activated) receives FDA approval
Health systems establish rigid guidelines for Xigris
Guidelines for drotrecogin alfa (activated) — Xigris
Feds revising drug discount proposal
News from the ASHP Midyear Clinical Meeting
News Briefs: FDA issues stronger warnings for droperidol
News Briefs: Postal workers see side effects from Cipro
News Briefs: Lamotrigine who?
Drug Criteria & Outcomes: Tinzaparin formulary evaluation: DVT treatment
Drug Criteria & Outcomes: In the Pipeline

Financial Disclosure: None of the authors or planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients

Shop Now: Search Products

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements

Emergency
Hospital
Clinical
All Access
Help
Search
About Us
Newsletters
FreeCME

The trusted source for healthcare information and CONTINUING EDUCATION.

ACCOUNTS RECEIVABLE

MAILING ADDRESS

1010 Sync St., Suite 100

Morrisville, NC 27560-5468

USA

© 2025 Relias. All rights reserved.

Do Not Sell My Personal Information
Privacy Policy
Terms Of Use
Help
Group Sales

For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

We use cookies to create a better experience. By continuing to use our site, you consent to the use of cookies outlined in our Privacy Policy.

Close Banner